MMED:CC News and Press, MIND MEDICINE INC. From 06/01/23

Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team...

Details Why MindMed’s Ideally Qualified Nominees Are the Right Choice to Oversee the Company’s Strategic Execution as it Approaches First Clinical Data Readouts Later this Year Urges Shareholders to Protect Their Investments and Vote on the WHITE Universal Proxy Card...

Independent Third-Party Firm, Led by Former Senior FDA Officials, Calls Phase 2b Trial “Well-designed” and “Essential” Report Further Demonstrates that FCM’s Proposal to Skip Phase 2 for MM-120 – a Cornerstone of its Plan – is Unrealistic a...

– Preclinical data in ASD model demonstrate prosocial effects of MM-402 – Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates t...

Research into psychedelics has increased significantly in the recent years, as we learn more about their beneficial properties. Before the psychedelic renaissance, trials on the effectiveness of psilocybin were conducted in the 1960s. However, research grinded to a halt following the classifica...

– Over 50% of patients dosed across 20 active clinical sites – – On Track for Topline Results in late 2023 – Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopha...

Legislators in Vermont recently discussed a bill to legalize psilocybin and begin offering regulated access to the drug. The state of Vermont is one of many states where legislators have shown interest in advancing psychedelic reform. The bill in question, H. 371 , was sponsored by Representativ...

Clerkenwell Health , a psychedelic-specialist clinical research firm, recently partnered with MYndspan, which will give medical researchers access to magnetoencephalography (MEG) scanners. MYndspan is a brain analytics firm that allows users to evaluate and monitor brain health to extend the he...

– Key MM-120 readouts in GAD (Phase 2b) and ADHD (Phase 2a) expected by end of 2023 – – MM-402 pre-clinical data in ASD model to be presented at ASCP 2023 Annual Meeting – – Strengthened leadership team with appointment of Mark R. Sullivan as...

Files Definitive Proxy Materials in Connection with June 15, 2023 Annual Meeting Board’s Nominees Possess Essential Pharmaceutical Industry, Capital Allocation and Corporate Governance Experience Needed to Drive Company’s Success at Pivotal Moment – With Two Key Clini...